Biomarkers in colorectal cancer
- PMID: 11220650
Biomarkers in colorectal cancer
Abstract
Epidemiological studies have revealed that the major dietary constituents implicated in colorectal carcinogenesis are fat/red meat (causative) and calcium/fibre (protective). Biomarkers have been used in both animal studies and clinical trials to investigate the effect of dietary factors and chemotherapeutic agents on colon carcinogenesis. They can be used as short-term end-points when investigations based on the development of cancer are not feasible. Although they can help in elucidating dietary or pharmacological effects, important results should be confirmed with longer-term studies. Colon cancer develops through an adenoma-carcinoma sequence. The appearance of colonic polyps in individuals at risk for colon cancer has been used as an end-point in clinical trials to assess diets and pharmacological agents for their effect on colon carcinogenesis. Normal-appearing mucosa can contain small foci of aberrant crypts, which can be dysplastic and thought of as microadenomas. The appearance and growth of such foci have been used to assess the effect of dietary factors and chemopreventive agents in experimental animals. Increased proliferation both increases the sensitivity of the colon to carcinogenesis and may represent an early step in colon carcinogenesis. Etheno-DNA adducts are an end-product of lipid peroxidation processes, and are strongly pro-mutagenic lesions. High dietary levels of n-6 fatty acids appear to be important here and may also increase eicosanoid or isoprostane exposure and provide a selective growth stimulus for tumour precursor cells. Low dietary calcium may lead to inhibition of apoptosis and possibly to an increase in cell proliferation. In three recently completed intervention trials, calcium moderately reduced the recurrence of adenomas, but in one study fibre increased recurrence dramatically.
Similar articles
-
Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids.Cancer Res. 2001 Mar 1;61(5):1927-33. Cancer Res. 2001. PMID: 11280748
-
Early events in human colorectal carcinogenesis. Aberrant crypts and microadenoma.Ital J Gastroenterol. 1992 Nov-Dec;24(9):498-501. Ital J Gastroenterol. 1992. PMID: 1489980 Review.
-
Intermediate effect markers for colorectal cancer.IARC Sci Publ. 2001;154:113-29. IARC Sci Publ. 2001. PMID: 11220651 Review.
-
Transforming growth factor alpha distribution in rectal crypts as a biomarker of decreased colon cancer risk in patients consuming cellulose.Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):633-7. Cancer Epidemiol Biomarkers Prev. 1997. PMID: 9264277 Clinical Trial.
-
Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.Am J Gastroenterol. 2005 Jun;100(6):1283-9. doi: 10.1111/j.1572-0241.2005.40891.x. Am J Gastroenterol. 2005. PMID: 15929758
Cited by
-
Isoprostane generation and function.Chem Rev. 2011 Oct 12;111(10):5973-96. doi: 10.1021/cr200160h. Epub 2011 Aug 18. Chem Rev. 2011. PMID: 21848345 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical